These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10932925)
21. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
23. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926 [TBL] [Abstract][Full Text] [Related]
24. Who needs to care about small, dense low-density lipoproteins? Rizzo M; Berneis K Int J Clin Pract; 2007 Nov; 61(11):1949-56. PubMed ID: 17935554 [TBL] [Abstract][Full Text] [Related]
25. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Backes JM; Gibson CA Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087 [TBL] [Abstract][Full Text] [Related]
29. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Devroey D; Velkeniers B; Duquet W; Betz W Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669 [TBL] [Abstract][Full Text] [Related]
30. Bridging the gap in treatment options for patients with hypertriglyceridemia. Underberg JA; Hays R J Fam Pract; 2007 Dec; 56(12 Suppl New):S24-31. PubMed ID: 18664339 [TBL] [Abstract][Full Text] [Related]
31. [Hypertriglyceridemia--diagnostics, risk and treatment]. Hexeberg S; Retterstøl K Tidsskr Nor Laegeforen; 2004 Nov; 124(21):2746-9. PubMed ID: 15534665 [TBL] [Abstract][Full Text] [Related]
32. Lipid disturbances in chronic renal failure--patomechanisms and treatment. Rutkowski B; Chmielewski M Rocz Akad Med Bialymst; 2004; 49():139-44. PubMed ID: 15631330 [TBL] [Abstract][Full Text] [Related]
33. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046 [TBL] [Abstract][Full Text] [Related]
34. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related]
35. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES Neth J Med; 2004; 62(7):229-34. PubMed ID: 15554597 [TBL] [Abstract][Full Text] [Related]
36. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. McKenney JM; Sica D Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707 [TBL] [Abstract][Full Text] [Related]
37. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]